Table 1. Genes selected for methylation... | American Society of Hematology

Table 1.

Genes selected for methylation analysis in acute myeloid leukemia

Gene	Chromosome	Function	Primers (F/R)	Annealing (temperature, no. cycles)	Restriction enzyme
CACNA1G	17q21	T-type calcium channel	GGGGGYGTTTTTTTTYGGATTTT	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	EcoRI
CACNA1G	17q21	T-type calcium channel	TTCCCCTACRCCCCTAAAACTTCC	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	EcoRI
ER-alpha	6q25	Estrogen receptor	GGTTTTTGAGTTTTTTGTTTTG	60 (3), 57 (4), 54 (5), 51 (25), 30 sec	TaqI
ER-alpha	6q25	Estrogen receptor	AACTTACTACTATCCAAATACACCTC	60 (3), 57 (4), 54 (5), 51 (25), 30 sec	TaqI
GPR37	7q31	G-protein–coupled receptor	GGTTAGGTGGGGTAAGAGTTT	56, 45 sec, 35 cycles	HinfI
GPR37	7q31	G-protein–coupled receptor	AACRTTTAATCCAATTACAAACC	56, 45 sec, 35 cycles	HinfI
MDR1	7q21	Drug efflux	GTTATAGGAAGTTTGAGTTT	54 (3), 51 (4), 48 (5), 45 (26), 30 sec	TaqI
MDR1	7q21	Drug efflux	AAAAACTATCCCATAATAAC	54 (3), 51 (4), 48 (5), 45 (26), 30 sec	TaqI
MINT1	5q13	CpG island hypermethylated in cancer	GGGTTGGAGAGTAGGGGAGTT	55 (35) 30 sec	TaqI
MINT1	5q13	CpG island hypermethylated in cancer	CCATCTAAAATTACCTCRATAACTTA	55 (35) 30 sec	TaqI
MINT2	2p22	CpG island hypermethylated in cancer	YGTTATGATTTTTTTGTTTAGTTAAT	60 (3), 58 (4), 56 (5), 54 (26)	TaqI
MINT2	2p22	CpG island hypermethylated in cancer	TACACCAACTACCCAACTACCTC	60 (3), 58 (4), 56 (5), 54 (26)	TaqI
MLH1	3p21	Mismatch repair	TAGTAGTYGTTTTAGGGAGGGA	53 (35) 30 sec	RsaI
MLH1	3p21	Mismatch repair	TCTAAATACTCAACRAAAATACCTT	53 (35) 30 sec	RsaI
MyoD	11p15	Muscle-specific transcription factor	TGTTGGAGAGGTTTGGAAAGG	53, 30 sec, 35 cycles	RsaI
MyoD	11p15	Muscle-specific transcription factor	AAAATCCRAAACCAATAAAAACAC	53, 30 sec, 35 cycles	RsaI
p15	9p21	Cyclin-dependent kinase inhibitor	GGAGTTTAAGGGGGTGGG	50, 30 sec, 35 cycles	NruI
p15	9p21	Cyclin-dependent kinase inhibitor	CCTAAATTACTTCTAAAAAAAAAC	50, 30 sec, 35 cycles	NruI
p16	9p21	Cyclin-dependent kinase inhibitor	GGTTTTGGYGAGGGTTGTTT	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	TaqI
p16	9p21	Cyclin-dependent kinase inhibitor	ACCCTATCCCTCAAATCCTCTAAAA	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	TaqI
PITX2	4q25	Homeotic gene	TAAGTGTTTYGTTAGGTTTTTT	50, 30 sec, 35 cycles	TaqI
PITX2	4q25	Homeotic gene	CCAAACTCCACTACACAATAAC	50, 30 sec, 35 cycles	TaqI
PTC-A	9q22	WNT signaling	GTTGGTTTGTTAATYGGAGT	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	TaqI
PTC-A	9q22	WNT signaling	TTACCAACCRAAACCATATT	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	TaqI
PTC-B	9q22	WNT signaling	5-AATGTGTGGAATTTAGGGA	54, 45 sec, 35 cycles	HgaI
PTC-B	9q22	WNT signaling	TAAAACAACCAACTACAACTTAC	54, 45 sec, 35 cycles	HgaI
SDC4	20q12	Cell surface heparan sulfate proteoglycan	GGGGATTTGTTTGGTAGTGG	57, 45 sec, 35 cycles	HinfI
SDC4	20q12	Cell surface heparan sulfate proteoglycan	CCCGAAATTCCCCAATAAA	57, 45 sec, 35 cycles	HinfI
THBS1	15q15	Angiogenesis inhibitor	GGAGAGAGGAGTTTAGATTGGTT	54, 45 sec, 38 cycles	BstUI
THBS1	15q15	Angiogenesis inhibitor	AAATAAAAATTACTCCTAAAAAAC	54, 45 sec, 38 cycles	BstUI

Gene	Chromosome	Function	Primers (F/R)	Annealing (temperature, no. cycles)	Restriction enzyme
CACNA1G	17q21	T-type calcium channel	GGGGGYGTTTTTTTTYGGATTTT	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	EcoRI
CACNA1G	17q21	T-type calcium channel	TTCCCCTACRCCCCTAAAACTTCC	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	EcoRI
ER-alpha	6q25	Estrogen receptor	GGTTTTTGAGTTTTTTGTTTTG	60 (3), 57 (4), 54 (5), 51 (25), 30 sec	TaqI
ER-alpha	6q25	Estrogen receptor	AACTTACTACTATCCAAATACACCTC	60 (3), 57 (4), 54 (5), 51 (25), 30 sec	TaqI
GPR37	7q31	G-protein–coupled receptor	GGTTAGGTGGGGTAAGAGTTT	56, 45 sec, 35 cycles	HinfI
GPR37	7q31	G-protein–coupled receptor	AACRTTTAATCCAATTACAAACC	56, 45 sec, 35 cycles	HinfI
MDR1	7q21	Drug efflux	GTTATAGGAAGTTTGAGTTT	54 (3), 51 (4), 48 (5), 45 (26), 30 sec	TaqI
MDR1	7q21	Drug efflux	AAAAACTATCCCATAATAAC	54 (3), 51 (4), 48 (5), 45 (26), 30 sec	TaqI
MINT1	5q13	CpG island hypermethylated in cancer	GGGTTGGAGAGTAGGGGAGTT	55 (35) 30 sec	TaqI
MINT1	5q13	CpG island hypermethylated in cancer	CCATCTAAAATTACCTCRATAACTTA	55 (35) 30 sec	TaqI
MINT2	2p22	CpG island hypermethylated in cancer	YGTTATGATTTTTTTGTTTAGTTAAT	60 (3), 58 (4), 56 (5), 54 (26)	TaqI
MINT2	2p22	CpG island hypermethylated in cancer	TACACCAACTACCCAACTACCTC	60 (3), 58 (4), 56 (5), 54 (26)	TaqI
MLH1	3p21	Mismatch repair	TAGTAGTYGTTTTAGGGAGGGA	53 (35) 30 sec	RsaI
MLH1	3p21	Mismatch repair	TCTAAATACTCAACRAAAATACCTT	53 (35) 30 sec	RsaI
MyoD	11p15	Muscle-specific transcription factor	TGTTGGAGAGGTTTGGAAAGG	53, 30 sec, 35 cycles	RsaI
MyoD	11p15	Muscle-specific transcription factor	AAAATCCRAAACCAATAAAAACAC	53, 30 sec, 35 cycles	RsaI
p15	9p21	Cyclin-dependent kinase inhibitor	GGAGTTTAAGGGGGTGGG	50, 30 sec, 35 cycles	NruI
p15	9p21	Cyclin-dependent kinase inhibitor	CCTAAATTACTTCTAAAAAAAAAC	50, 30 sec, 35 cycles	NruI
p16	9p21	Cyclin-dependent kinase inhibitor	GGTTTTGGYGAGGGTTGTTT	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	TaqI
p16	9p21	Cyclin-dependent kinase inhibitor	ACCCTATCCCTCAAATCCTCTAAAA	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	TaqI
PITX2	4q25	Homeotic gene	TAAGTGTTTYGTTAGGTTTTTT	50, 30 sec, 35 cycles	TaqI
PITX2	4q25	Homeotic gene	CCAAACTCCACTACACAATAAC	50, 30 sec, 35 cycles	TaqI
PTC-A	9q22	WNT signaling	GTTGGTTTGTTAATYGGAGT	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	TaqI
PTC-A	9q22	WNT signaling	TTACCAACCRAAACCATATT	58 (5), 56 (5), 54 (5), 52 (26), 30 sec	TaqI
PTC-B	9q22	WNT signaling	5-AATGTGTGGAATTTAGGGA	54, 45 sec, 35 cycles	HgaI
PTC-B	9q22	WNT signaling	TAAAACAACCAACTACAACTTAC	54, 45 sec, 35 cycles	HgaI
SDC4	20q12	Cell surface heparan sulfate proteoglycan	GGGGATTTGTTTGGTAGTGG	57, 45 sec, 35 cycles	HinfI
SDC4	20q12	Cell surface heparan sulfate proteoglycan	CCCGAAATTCCCCAATAAA	57, 45 sec, 35 cycles	HinfI
THBS1	15q15	Angiogenesis inhibitor	GGAGAGAGGAGTTTAGATTGGTT	54, 45 sec, 38 cycles	BstUI
THBS1	15q15	Angiogenesis inhibitor	AAATAAAAATTACTCCTAAAAAAC	54, 45 sec, 38 cycles	BstUI

View Large

This Feature Is Available To Subscribers Only